Kalaris director granted options on 9,000 shares
Kalaris Therapeutics, Inc. director Michael Dybbs received a grant of stock options representing 9,000 shares of Common Stock.
Rhea-AI Filing Summary
Kalaris Therapeutics, Inc. director Michael Dybbs received a grant of stock options representing 9,000 shares of Common Stock. The options have an exercise price of $4.72 per share and expire on June 2, 2036.
The shares underlying the option are scheduled to vest in full on the earlier of June 3, 2027 or the date of Kalaris Therapeutics' 2027 Annual Meeting of Stockholders, provided he continues to serve the company through that time. Following this grant, he holds 9,000 derivative securities directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 9,000 shares
Grant/Award
1 txn
Insider
Dybbs Michael
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 9,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 9,000 contracts (Direct)
Footnotes (1)
- F1. The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.
Key Figures
Options granted: 9,000 options
Exercise price: $4.72 per share
Expiration date: June 2, 2036
+2 more
5 metrics
Options granted
9,000 options
Grant to director Michael Dybbs on June 3, 2026
Exercise price
$4.72 per share
Stock option strike price for KLRS Common Stock
Expiration date
June 2, 2036
Option term end for 9,000-share grant
Underlying shares
9,000 shares
Common Stock underlying granted options
Post-grant derivative holdings
9,000 options
Total derivative securities held after transaction
Key Terms
Stock Option (Right to Buy), exercise price, Common Stock, Annual Meeting of Stockholders, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "4.7200""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Annual Meeting of Stockholders financial
"the date of the Issuer's 2027 Annual Meeting of Stockholders"
vest in full financial
"shares underlying the option are scheduled to vest in full"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did KLRS director Michael Dybbs report?
Director Michael Dybbs reported receiving stock options for 9,000 Kalaris Therapeutics shares. These options were granted as a compensation award, giving him the right to buy Common Stock at a fixed exercise price if the options vest and are later exercised.
How many Kalaris Therapeutics (KLRS) options were granted to Michael Dybbs?
Michael Dybbs was granted options covering 9,000 shares of Kalaris Therapeutics Common Stock. This award increases his derivative holdings to 9,000 options, all related to this grant, and reflects compensation rather than an open-market stock purchase or sale.
What is the exercise price of Michael Dybbs’ KLRS stock options?
The exercise price of Michael Dybbs’ stock options is $4.72 per Kalaris Therapeutics share. This means he can purchase Common Stock at $4.72 per share if the options vest and he chooses to exercise them before they expire in 2036.
When do Michael Dybbs’ Kalaris Therapeutics (KLRS) options vest?
The options are scheduled to vest in full on the earlier of June 3, 2027 or the date of Kalaris Therapeutics’ 2027 Annual Meeting of Stockholders. Vesting is conditioned on his continued service with the company through the applicable vesting date.
When do the KLRS stock options granted to Michael Dybbs expire?
The stock options granted to Michael Dybbs expire on June 2, 2036. He may choose to exercise them at any point after they vest and before this expiration date, subject to the terms of the option agreement and company equity plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
